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A recent study by Gabel et al. (2015) found that Mecp2, the gene mutated in Rett syndrome, represses long
(> 100 kb) genes associated with neuronal physiology and connectivity by binding to methylated CA sites in
DNA. This study adds to a growing body of literature implicating gene length and transcriptional mechanisms
in neurodevelopmental and neurodegenerative disorders.Mutations in methyl-CpG-binding protein
2 (MECP2) cause Rett syndrome, an
X-linked neurodevelopmental disorder
associated with synaptic dysfunction,
intellectual disability, and autism symp-
toms (Chahrour and Zoghbi, 2007). While
MECP2 is known to function as a tran-
scriptional repressor, precisely how the
loss of MECP2 impairs synaptic function
at the level of gene expression has re-
mained unclear. This question has taken
on greater relevance now that de novo
mutations in numerous transcriptional
regulators were identified in individuals
with autism (De Rubeis et al., 2014; Iossi-
fov et al., 2014), a disorder that is also
associated with dysfunctional synapses
(Chen et al., 2015; Delorme et al., 2013).
New insights into this question were
inspired by recent findings on topoiso-
merases—a class of enzymes that relieve
supercoiling during DNA replication and
transcription, and that are implicated
in autism, intellectual disability, schizo-
phrenia, and neurodegeneration (Katyal
et al., 2014; King et al., 2013; Neale
et al., 2012; Stoll et al., 2013). In particular,
topoisomerase inhibitors were recently
shown to reduce the expression of
extremely long (> 100 kb) genes in cortical
neurons by impairing transcription elon-
gation (King et al., 2013). Many of these
long genes were associated with neuronal
development and synapses, including
several autism candidate genes like
Neurexin-1, Neurexin-3, and Neuroligin-1
(King et al., 2013). These findings sug-
gested that a length-dependent impair-
ment of gene transcription, particularly in
neural tissues and neurons where longer
genes are overrepresented (Figures 1
and 2) (Gabel et al., 2015), might impairsynaptic function and contribute to
neurodevelopmental disorders. In sup-
port of this possibility, topoisomerase
inhibition reversibly depletes Neurexin-1
and Neuroligin-1 at the protein level
and reversibly impairs synaptic function
(Mabb et al., 2014).
With these new perspectives on how
transcriptional deficits can affect long
genes in neurons, the labs of Michael
Greenberg and Sacha Nelson, working
independently, examined gene expres-
sion data from Mecp2-null mice (Gabel
et al., 2015; Sugino et al., 2014). Remark-
ably, they found that long genes were
modestly, but reproducibly, upregulated,
with an inflection point around 100 kb.
Gabel and colleagues performed a
number of genome-wide studies and
re-analyzed numerous existing data sets
to convincingly demonstrate a direct
relationship between MECP2 function,
gene length, and disease severity. This
included examining gene expression
data from Mecp2 knockout mice,
two mouse lines with Rett syndrome
nonsense mutations (R270X and G273X),
a mouse line with a Rett syndrome
missense mutation (R306C), cultured
human neurons derived from embryonic
stem cells lacking Mecp2, and brain
tissue from individuals with Rett syn-
drome. They also found that long gene
transcription was repressed in a mouse
model of Mecp2 duplication syndrome.
These studies provide strong evidence
that the transcriptional repressor function
of MECP2 is biased toward longer tran-
scripts. Gabel and colleagues also found
that Fmrp, the gene mutated in fragile X
syndrome, targets genes that are longer
than average (Gabel et al., 2015). Collec-Neurontively, these studies extend the concept
that transcriptional deficits can affect
gene expression in a length-dependent
manner, and may represent a common
mechanism associated with neurodeve-
lopmental disorders.
Both groups also found thatmany of the
upregulated long genes in Mecp2-defi-
cient neurons and brain tissues are
involved in cell adhesion, axon guidance,
and synapse formation (Gabel et al.,
2015; Sugino et al., 2014). It is now well
recognized that changes in synapse
number can affect excitatory and inhibi-
tory balance in the brain (Gogolla et al.,
2009). As such, a small increase in
expression across a large number of
long synaptic genes could upset excit-
atory/inhibitory balance and impair syn-
apse function, as is seen in Rett model
mice (Chahrour and Zoghbi, 2007). These
studies thus provide new insights into
how Mecp2 loss could transcriptionally
impair synaptic function.
Gabel et al. (2015) also found that
mouse and human brains express a
greater proportion of long genes relative
to non-neural tissues. We found this holds
true when a larger number of brain re-
gions, tissues, and cell types is examined
(Figure 1). The transcriptomes of frontal
cortex and amygdala, two brain regions
implicated in autism and other neuro-
developmental disorders (Chen et al.,
2015), are particularly biased for longer
transcripts relative to other brain regions.
To better understand which brain cell
types contribute to this length bias,
we re-analyzed the transcriptomes of
the nine major cell types that make up
the mouse cerebral cortex and CA1
region of the hippocampus, as defined in86, April 22, 2015 ª2015 Elsevier Inc. 353
Figure 1. The Transcriptome of Neural Tissues Is Biased for Longer Transcripts Relative to Non-neural Tissues and Cell Lines
Mouse expression data were obtained from BioGPS (Su et al., 2004). Expression intensity for each gene in a given tissue was compared to gene length, and
Pearson correlation coefficients were computed. Positive values indicate a positive correlation between gene expression and gene length.
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et al., 2015). Intriguingly, we found that
the transcriptome of each major neuron
subtype is biased for longer transcripts
relative to non-neuronal cell types (Fig-
ure 2). Moreover, the transcriptome of
hippocampal pyramidal neurons is signif-
icantly longer than that of somatosensory
cortex pyramidal neurons (Figure 2). This
mirrors the length bias seen at the
whole-tissue level (Figure 1). Thus, tran-
scriptome length biases can be used
to distinguish brain regions and individual
neuron subtypes from one another
as well as from non-neuronal cells.
These findings raise the possibility that
brain regions and neuron subtypes with
longer transcriptomes may be more
sensitive to transcriptional deficits, such
as those caused by Mecp2 deficiency or
overexpression.
These transcriptional deficits preferen-
tially affect genes that are 100 kb or
larger, raising the question of how the
transcriptional machinery ‘‘senses’’ gene
size. Or more accurately, what mole-
cularly distinguishes an extremely long354 Neuron 86, April 22, 2015 ª2015 Elseviergene from an average-length gene?
Gabel and colleagues provide important
new insight into this question by showing
that the density of methylated CA (mCA)
sites is higher over long gene bodies
when compared to short gene bodies
(Gabel et al., 2015). Their data provide
compelling evidence that MECP2 binds
these mCA sites, effecting greater repres-
sion as the density of mCA goes up with
gene length. One way they supported
this model was by examining gene
expression in mice deficient in Dmnt3a,
the enzyme that generates the methyl-
ation mark. Dmnt3a loss led to upregula-
tion of long genes, thus phenocopying
Mecp2 deletion. Their data therefore pro-
vide compelling evidence that epigenetic
marks on the gene body are recognized
by MECP2 and promote gene-length-
dependent transcriptional repression by
MECP2.
Lastly, Gabel et al. (2015) ended their
study with a therapeutic twist. Knowing
that the topoisomerase inhibitor topote-
can dose-dependently downregulates
long genes (King et al., 2013), theyInc.showed it was possible to normalize
expression of eight MECP2-repressed
genes with low concentrations of topote-
can. Ultimately, the success of such
a strategy for rescuing Rett syndrome
phenotypes will depend on how many
long genes are shared between the two
conditions, and whether these shared
long genes drive the phenotypes under
study. Regardless, this proof of concept
demonstrates that a pharmacological
normalization of multiple MECP2-relevant
genes is possible.
Taken together, these new studies
provide key insights into how mutations
in transcriptional regulators could impair
synaptic physiology and brain develop-
ment by altering the expression of
numerous long genes. Loss of genes
linked to amyotrophic lateral sclerosis
(TDP-43 and FUS/TLS) preferentially
affects splicing of transcripts with long
(> 100 kb) first introns (Lagier-Tourenne
et al., 2012), suggesting that gene length
is a factor in neurodegenerative disorders
as well. Thus, it is becoming clear
that several transcriptional mechanisms
Figure 2. The Transcriptome of Neurons Is
Biased for Longer Transcripts Relative to
Other Brain Cell Types
Oligoden., oligodendrocytes. Hippocampal CA1
versus somatosensory (SS) pyramidal neurons,
*p < 0.005 by two-sample t test. Error bars are
SEM. Gene expression data were obtained from
http://linnarssonlab.org/blobs/cortex/expression_
mRNA_17-Aug-2014.txt. Total read counts were
computed for each cell by taking the sum of all
counts for all RefSeq genes, and individual gene
values were normalized by this sum. Genes shorter
than 500 bp in length were excluded from the anal-
ysis. Gene-length Pearson correlations for each
of the 3,005 individual cells were then computed.
Values were averaged and plotted for each of the
nine cell classes as defined in Zeisel et al. (2015).
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Previewsassociated with gene length (transcription
elongation, transcriptional repression,
splicing, and epigenetic mark deposition)
represent major molecular points of
vulnerability for neurons as well as targetsfor therapeutic intervention, particularly in
the context of neurodevelopmental and
neurodegenerative disorders.
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